Tauklarify (florquinitau F 18 injection) is a brain PET tracer approved in 2026 to help identify tau tangles in adults with thinking problems who are being checked for Alzheimer's disease. Tau tangles are twisted clumps of tau protein that build up inside brain cells. Lantheus reported the August 14, 2026 approval for this use in adults with cognitive impairment the FDA approval notice.
The tracer makes clumped tau visible on PET images. It is a diagnostic tool only and does not treat Alzheimer's. It adds tau information alongside other parts of a memory workup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan show?
- How accurate is the reading?
- What are the side effects and prep steps?
- What questions can you bring to the clinic?
What does the scan show?
The tracer travels through the blood and sticks to clumped tau protein. A PET camera then records where that signal appears in the brain. NeurologyLive explains that florquinitau F 18 binds aggregated tau and is diagnostic only, not a treatment the NeurologyLive summary. A reader trained in PET images scores the pattern as positive or negative for tau tangle pathology.
That result joins memory tests, exams, brain scans, and often amyloid testing. A positive tau image supports Alzheimer's pathology, while a negative image points away from widespread tangles. This is not a stand-alone answer. Brain changes overlap, and symptoms still guide care. Ask what your full test pattern shows, not only one image.
How accurate is the reading?
Approval rested on blinded reads of images from 617 people across three trials. Five independent readers scored the scans without knowing clinical details. According to Pharmacy Times, positive agreement ranged from 68% to 88% and negative agreement from 93% to 99%, with strong reader consistency the Pharmacy Times report. That pattern matters for families.
Negative reads agreed more often than positive reads. Performance can be lower earlier in disease, when tangles are fewer. Safety and effectiveness are not established for tau diseases other than Alzheimer's. A negative scan does not rule out tau pathology, and a positive scan does not prove it alone. Misreading remains possible, so the clinic should explain false positives and false negatives.
What are the side effects and prep steps?
In 1,734 exposed subjects, Pharmacy Times reports headache in 0.7% and nausea in 0.2% of people. Labeling also warns about misdiagnosis risk and cancer risk from added radiation exposure. Clinics advise drinking water and urinating often after dosing to clear the tracer faster. Prep includes medicines and smoking.
Patients must avoid CYP1A2 inducers, including tobacco smoking, for at least 7 days before dosing. People who are nursing are advised to pause breastfeeding for 4 hours after the injection. Tell the team about smoking, vaping, herbal products, prescription drugs, pregnancy, and breastfeeding. Bring a full list with doses and stop dates. Ask what to do if a dose is missed or exposure happens.
What questions can you bring to the clinic?
Tauklarify is the second FDA-approved tau PET tracer after Tauvid from 2020, and SNMMI describes it as complementing amyloid PET the SNMMI announcement. Commercial timing may vary by center, so ask whether your clinic offers it now or plans to offer it soon.
Bring these short questions on paper and take notes: Ask for a plain-language result letter. Keep the image report with your medication list and advance directives.
- Am I in the intended group: cognitive impairment being evaluated for Alzheimer's?
- How will tau PET change my diagnosis, care plan, or trial options?
- Should I also have amyloid PET, spinal fluid testing, or MRI?
- Who reads the scan, and how often do readers disagree?
- What do my smoking, medicines, pregnancy, or nursing mean for scheduling?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Memory Clinic Patients Can Bring to a Clinician
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Memory Clinic Patients Can Bring to a Clinician
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Memory Clinic Patients Should Know About the News
